Growth hormone stimulating peptides – fountain of youth or poisoned chalice?

Growth hormone, IGF-1, and cancer risk — what does the research actually say?

To understand the cancer concern, you first need to understand IGF-1 (Insulin-like Growth Factor 1). When growth hormone is released, it signals the liver to produce IGF-1, which is responsible for most of growth hormone’s growth-promoting effects. IGF-1 drives cells to grow and divide — and critically, it suppresses apoptosis, the process by which damaged or abnormal cells self-destruct. In other words, elevated IGF-1 doesn’t just help your muscles grow; it creates an environment where pre-cancerous cells are more likely to survive and proliferate too (R).

Various cancers — including breast, prostate, colorectal, and thyroid — overexpress receptors for both GH and IGF-1, making them particularly sensitive to growth-promoting signals (R).

The most instructive real-world evidence comes from acromegaly — a condition where the pituitary gland produces chronically excessive growth hormone. A 2025 study comparing over 10,000 acromegaly patients to matched controls found significantly elevated cancer rates across multiple cancer types (R):

• 3.3x higher risk of leukaemia or lymphoma
• 1.9x higher risk of ovarian cancer
• 1.8x higher risk of breast cancer
• 1.9x higher risk of lung cancer
• 1.5x higher risk of prostate cancer

Some of these cancers also appeared significantly earlier — ovarian cancer on average 7.2 years earlier, liver cancer 6.3 years earlier.

Now, acromegaly involves extreme, uncontrolled growth hormone excess — very different from the modest, pulsatile stimulation that CJC-1295 and Ipamorelin produce. But the data is nonetheless sobering, because it illustrates what chronic growth hormone and IGF-1 elevation can do over time. And when these peptides are used at supraphysiological doses — more than what’s needed to restore normal levels — they begin to mimic exactly that state.

Conversely, and fascinatingly, the flip side of this story supports the same conclusion from the opposite direction. Individuals with Laron syndrome — a genetic condition causing GH receptor dysfunction and severely diminished growth hormone and IGF-1 signalling — display a markedly reduced incidence of cancer (R). Less growth hormone activity, less cancer. The biology appears consistent.

However, peptides that stimulate growth hormones appear to work somewhat differently from direct growth hormone injections.

Growth hormone, much like many other hormones including cortisol or melatonin, has a natural daily rhythm, meaning it isn’t released to the same amount all day and night long, but in fact mostly released at night (during the deep sleep phase). It appears that the peptides CJC-1295 and ipamorelin preserve that natural pulsatility, which may mitigate some of the risks (R, R).

For people using CJC-1295 and Ipamorelin at low doses to restore declining GH levels — not to exceed them — the jury is still out.

Who should likely avoid CJC-1295 and Ipamorelin?

Given the current evidence, I would be particularly cautious — and likely avoid these peptides altogether — if any of the following apply:

• Personal or family history of cancer, particularly hormone-sensitive cancers such as breast, prostate, colorectal, or thyroid. Given the IGF-1/cancer biology, this might not be a theoretical risk worth taking.
• Pre-diabetes, insulin resistance, or type 2 diabetes. Growth hormone elevates blood sugar by opposing insulin’s effects. If your metabolic health is already compromised, adding a GH stimulus on top is likely to make things worse.
• Active inflammatory conditions. GH and IGF-1 can amplify inflammatory signalling — not what you want if inflammation is already part of your health picture.

But the honest answer is that we simply don’t have long-term human safety data for these specific peptides, even when administering in low doses to substitute for age related decline.

And given what we know about the growth hormone/ IGF-1 axis, caution is warranted. A safer option may be to stick to natural growth hormone supporting strategies, that have a proven track record of helping health span, longevity, body composition and wellbeing, without any potentially disastrous side effects.

Before you consider peptides — What moves the needle naturally. The real fountain of youth?

It’s worth pausing here, because the basics genuinely matter more than most people give them credit for.

The majority of your body’s daily growth hormone is secreted in large pulses during deep, slow-wave sleep — approximately 70% of nightly GH release occurs during that first deep sleep cycle (R). Miss it — through late nights, alcohol, or poor sleep hygiene — and no peptide is going to compensate for what you’re losing upstream.

A few evidence-based levers worth optimising before reaching for CJC-1295 or Ipamorelin:

• Prioritising sleep. Your circadian rhythm governs GH pulsatility. Going to bed and waking at the same time every day supports healthy GH production more reliably than most supplements (R). If you struggle with sleep, work with a Functional Medicine practitioner to address the root cause of why you cannot sleep. Common factors include excess histamine from chronic infections, gut microbiome imbalances, nutrient deficiencies and blood sugar dysregulation. Melatonin can be a helpful and safe adjunct, or if you want to step it up a notch, the peptide epitalon, which has been shown to help reset our circadian rhythm and sleep quality, without any potential health risks. If you are interested in finding out more on epitalon, read one of my latest blog posts on the topic here.